The FDA greenlights treatment-related changes in bone mineral density as a surrogate endpoint in anti-osteoporosis drug trials in postmenopausal women.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback